Y-mAbs Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-04-01
- Employees
- 100
- Market Cap
- $676.1M
- Website
- http://www.ymabs.com
- Introduction
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Clinical Trials
17
Trial Phases
2 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Non-hodgkin Lymphoma
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT05994157
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Corewell Health-BAMF Health, Grand Rapids, Michigan, United States
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
- Conditions
- SCLCMalignant MelanomaSarcomaHigh Risk Neuroblastoma
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT05130255
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- AML, Childhood
- Interventions
- Drug: CD33*CD3 BsAb
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT05077423
- Locations
- 🇺🇸
Children's of Alabama/University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸UCSF Benioff Children's Hospital, San Francisco, California, United States
131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma
- Conditions
- DIPG
- Interventions
- Device: Convention Enhanced Delivery
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT05063357
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT04909515
- Locations
- 🇭🇰
Hong Kong Children's Hospital, Kowloon, Hong Kong
🇰🇷Asan Medical Center Childrens Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- Next
News
SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for $412 Million, Expanding Rare Oncology Portfolio
SERB Pharmaceuticals announced an all-cash acquisition of Y-mAbs Therapeutics for $8.60 per share, representing a 105% premium and $412 million equity value.
Osteosarcoma Market Poised for Significant Growth Through 2034 as Novel Therapies Enter Pipeline
The osteosarcoma market in the 7MM is expected to grow significantly by 2034, driven by extensive R&D activities and the entry of novel therapies including OST-HER2, Naxitamab 15-096, and HALMB-0168.
Y-mAbs Presents Preclinical Pharmacokinetics Data for CD38-SADA Pretargeted Radioimmunotherapy at AACR 2025
Y-mAbs Therapeutics presented preclinical pharmacokinetics data for CD38-SADA at the 2025 AACR Annual Meeting, demonstrating key insights into the protein's behavior in animal models.
Y-mAbs Initiates Phase 1 Trial of CD38-SADA Radioimmunotherapy for Relapsed Non-Hodgkin Lymphoma
Y-mAbs Therapeutics has dosed the first patient in its Phase 1 trial of CD38-SADA PRIT platform for relapsed/refractory non-Hodgkin Lymphoma, marking its first clinical program in hematological malignancies.
Naxitamab Shows Promising Results in Phase 2 Trial for High-Risk Neuroblastoma
Phase 2 trial of naxitamab with GM-CSF achieved 50% overall response rate in patients with relapsed/refractory high-risk neuroblastoma, meeting its primary endpoint.
Biopharma Industry Faces Continued Layoffs in 2025 Amid Strategic Realignments
Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.